Zanolimumab: Difference between revisions
Content deleted Content added
Stickymatch (talk | contribs) m Spelling/grammar/punctuation/typographical correction |
Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB) |
||
Line 43: | Line 43: | ||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = 147 kg/mol |
|||
}} |
}} |
||
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4] {{webarchive |url=https://web.archive.org/web/20080516135546/http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx |date=May 16, 2008 }}</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It was developed with the goal of treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=Archived copy |accessdate=August 20, 2010 |url-status=dead |archiveurl=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archivedate=April 11, 2010 }}</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> Development of the drug was ultimately discontinued with termination of all trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4] {{webarchive |url=https://web.archive.org/web/20080516135546/http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx |date=May 16, 2008 }}</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It was developed with the goal of treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=Archived copy |accessdate=August 20, 2010 |url-status=dead |archiveurl=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archivedate=April 11, 2010 }}</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> Development of the drug was ultimately discontinued with termination of all trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
Revision as of 16:56, 19 June 2020
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine
- ^ "Archived copy". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.